Le Lézard
Classified in: Health, Science and technology, Business
Subjects: NEW PRODUCTS/SERVICES, CORPORATE OFFICERS

Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureustm Branded THC and CBD Extracts to Portugal


NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TORONTO, May 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. ("SMGH"), SMGH has completed its first commercial export of high concentration THC and high concentration CBD full spectrum psychoactive cannabis extracts to Portugal.

Lucas Nosiglia, President of Avicanna LATAM, commented: "We are happy to see the international opportunities for our Aureus-branded products continue to grow globally and more specifically in the European Union where we are well positioned. We believe that our comprehensive portfolio combined with our dedication to quality standards and organic and sustainable practices positions us well as a supplier for our global partnerships."

About Aureustm

Avicanna's supply chain business unit is based in Santa Marta, Colombia and provides a consistent source of cannabinoid raw materials for the global marketplace. These include active pharmaceutical ingredients and feminized seeds, for Avicanna's cosmetic, medical, and pharmaceutical products, in addition to supplying the company's partners around the world.

Aureus-branded products are cultivated, extracted, and manufactured by Avicanna's subsidiaries in Colombia where they leverage optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably and include a range of extracts of CBD, THC and rare cannabinoids such as CBG.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phytotm brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Truneroxtm) is in the drug registration stage in South America.

Click to watch Avicanna's Corporate Video 2022

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at [email protected] or follow us on social media on LinkedInTwitterFacebook or Instagram.

The Company posts updates through videos from the official Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated March 31, 2022 filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/35098bc5-f37d-4699-a457-1e74989b1d4b

 



These press releases may also interest you

at 16:35
Gilead Sciences, Inc. today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in...

at 16:35
ITHAX Acquisition Corp. ("ITHAX") today announced that its registration statement on Form S-4 (as amended, the "Registration Statement"), relating to the previously announced proposed business combination (the "Business Combination") of ITHAX with...

at 16:30
VERSES Technologies Inc. ("VERSES") is pleased to announce that the Neo Exchange Inc. (the "NEO Exchange" or "NEO") has granted final approval of VERSES' listing application, and that VERSES will commence trading on the NEO Exchange tomorrow under...

at 16:27
Gluware, Inc., the leader in intelligent network automation for the enterprise, will join Packet Pushers to present a livestream event on Tuesday, June 28, 2022, at 9:00 AM PDT/12:00 PM EDT, "Real-World Enterprise Automation: No-Code Process...

at 16:18
A new survey conducted by Protiviti and ISACA found that cybersecurity is the chief risk for IT audit departments, with several related risks such as privacy and data as well as regulatory compliance also ranking as top concerns....

at 16:15
Vagaro and Thrivo recently announced they will co-host a free Pride celebration at the first-ever Metaverse salon on June 30th to officially close out Pride Month. The virtual dance party will take place on the rooftop of the Thrivo Salon, located...



News published on 24 may 2022 at 07:30 and distributed by: